穗恆運A(000531.SZ):灣頂基金擬發起設立白鷺液氫科技創業投資基金
格隆匯1月28日丨穗恆運A(000531.SZ)公佈,2022年1月28日,公司第九屆董事會第十一次會議審議通過了《關於設立白鷺液氫科技創業投資基金的議案》。同意公司控股的廣州開發區灣頂新動能產業投資基金合夥企業(有限合夥)(“灣頂基金”)作為有限合夥人發起設立白鷺液氫科技創業投資基金(暫定名,“液氫基金”),基金總規模4.6億元,首期實繳6100.01萬元。灣頂基金認繳液氫基金1.5億元,由灣頂基金現有餘額出資,首期實繳液氫基金1866.67萬元,後續實繳視項目進展情況仍需履行相關決策程序。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.